Fighting Sickle Cell Disease with Gene Correction Technology

Thursday, November 16 @ 2-3pm ET

A cross-section drawing of a head where the brain and brainstem have been replaced with a tree.

Sickle cell disease is a monogenic blood disease, and is the most common serious blood disease in the world affecting 4.4 million people who have SCD, while an additional 43 million have sickle-cell trait as of 2015. Join Mark DeWitt of the Innovative Genomics Institute at UC Berkeley who is part of the team helping to develop a clinical protocol to correct the sickle cell disease mutation using CRISPR /Cas9 in hematopoietic stem cells.

What You Will Learn

  • How to efficiently gene edit hematopoietic stem cells
  • What are the key concerns with translating CRISPR to the clinic
  • Approaches to clinical translation of gene editing protocols in an academic setting through an ad hoc disease team

Benefits of Membership

  • ACS Webinars Archive: Every one of our 200+ past webinars available on demand
  • Save Money: Members receive discounts on meetings, development courses and more!
  • Access to SciFinder®: Members receive 25 complimentary SciFinder® research activities per year

The Fine Print

ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.

ACS Webinars Logo


Mark DeWitt
UC Berkeley

Alyson Weidmann
ACS Publications

Co-Produced With